A study led by researchers at the University of Pittsburgh and UPMC published today in JAMA Network Open, a peer-reviewed journal of the American Medical Association, found that vaccination against respiratory syncytial virus (RSV) during pregnancy reduced the risk of hospitalization in young infants by nearly 70%.

About The Study: Maternal respiratory syncytial virus prefusion F (RSVpreF) vaccination was associated with protection against RSV-associated acute respiratory illness and lower respiratory tract disease hospitalization among infants 90 days or younger. These findings provide early clinical evidence supporting the effectiveness of maternal RSVpreF vaccination in preventing RSV-associated hospitalization in infants.

About The Study: In this qualitative study of patient experiences with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), participants described GLP-1 RA therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. Quality of care was highly variable; thus, standardized guidelines for patient education and clinical support could improve expectation management around likely adverse effects and long-term management.

A randomized clinical trial conducted across five countries in 47 pediatric emergency departments, including Ann & Robert H. Lurie Children’s Hospital in Chicago, established that both commonly used IV fluids for treating septic shock – balanced crystalloid fluid and 0.9% saline – are equally safe and effective. Results were published in the New England Journal of Medicine.

Researchers at the California Department of Public Health developed a new, effective, and low-cost way to carry out whole genome sequencing for hantaviruses.

The American Heart Association launches stroke coordinator certification to elevate quality of stroke care